The groundbreaking discovery of all-trans retinoic acid as a potent inducer of in vivo differentiation in acute promyelocytic leukemia has provided the first proof of concept of clinically active differentiation therapy in cancer. 1 The vast majority of acute myeloid leukemia (AML) patients, however, are nonresponsive to single-agent all-trans retinoic acid or to other agents inducing differentiation in vitro.
We present the case of a 52-year-old male patient diagnosed in March 2006 with de novo AML, a white blood count (WBC) of 32 000/ml, 65% bone marrow (BM) blasts (highly expressing CD117/c-Kit), a 45,X,-Y, t(8;21)(q22;q22) karyotype, wildtype flt-3 and an activating c-Kit mutation (exon 17 N822K). According to the sequencing chromatogram (generated as previously described 2 ), the c-Kit mutation was only present in a sub-population of cells (data not shown). The patient relapsed three times after standard treatments, including allogeneic blood stem cell transplantation from a human leukocyte antigenidentical sibling in April 2007 and salvage treatment with topotecan and cytosine arabinoside in August 2007. Being faced with this highly chemo-resistant AML, we offered the patient palliative treatment with the multi-kinase inhibitor dasatinib (a known inhibitor of c-Kit 3 ) to control leukemic regrowth. After the patient gave informed consent, dasatinib was started on 13 September 2007, at a dose of 70 mg b.i.d. and 7 days later at 100 mg b.i.d., on the basis of the knowledge that in Core Binding Factor (CBF) leukemias, c-Kit is usually overexpressed and/or activated by point mutations; 4 either mechanism is considered to function as a 'second hit' oncogenic lesion complementing the leukemic fusion proteins RUNX1/RUNX1T1 (AML1/ETO) or CBFb/MYH11. 5 At that time, the subclone with the c-Kit exon 17 N822K mutation was no longer detectable by direct sequencing (not shown), indicating clonal evolution.
Within a week leukemic regrowth was mitigated, followed by progressive clearing of myeloid blasts and, surprisingly, appearance of morphologically unusual neutrophils in peripheral blood (Figure 1a) . On day 22 after the start of dasatinib, the patient also received a single dose of filgrastim. By virtue of this impressive and unexpected activity of dasatinib, the patient's white blood count could be stabilized over a total of 14 weeks, without any additional chemotherapy. Donor lymphocyte infusions were given twice, and he could be discharged to outpatient supportive care 7 weeks after initiation of dasatinib, albeit still erythrocyte-and platelet-transfusion dependent (donor lymphocyte infusions were given two more times). When leukocytosis recurred 7 weeks later, indicating dasatinib resistance, he succumbed to AML at home, having declined any further treatment or hospitalization.
The chromosomal translocation t(8;21) generates the fusion protein RUNX1/RUNX1T1, which mediates a block in granulocytic differentiation, 6 and the clinical course observed implicated a strong differentiating effect of dasatinib imposed on the leukemic clone. BM aspirates taken 10 and 30 days after initiation of dasatinib showed not only a decrease of leukemic blasts from 86% to o10% with high levels of c-Kit expression by flow cytometry and immunohistochemistry (Figure 1b ), but also expansion of more mature myelopoiesis and eosinophils ( Figure 1b i and ii) without evidence of a cytogenetic remission (not shown). To better understand this maturation process, sequential immunophenotyping of the myeloid blasts (strongly expressing c-Kit/CD117) was performed. Indeed the residual blast population (within the blast gate as defined by forward scatter (FSC)/side scatter (SSC) and still c-Kit positive) had undergone marked downregulation of CD34 (from 88 to 23%), concordant with partial maturation (Figure 1b v and vi) . Notably, aberrant expression of CD56 on the residual blasts also decreased from 60 to 34% (Figure 1b v and vi) . To address whether the emerging peripheral blood granulocytes were indeed derived from the malignant clone, fluorescence in situ hybridization analysis was performed on purified peripheral blood neutrophilic granulocytes, confirming that the translocation t(8;21) was present in 543/600 nuclei (91%), and a loss of the Y chromosome in 552/600 nuclei (92%, Figure 1c ). These neutrophilic granulocytes retained some phagocytic functional activity, as shown by both opsonophagocytic assay and oxidative burst activity ( Figure 1d ).
As induction of granulocytic differentiation by imatinib has been described via upregulation of CAAT-enhancer binding protein-a (C/EBPa), 7, 8 immunohistochemistry for C/EBPa expression was performed on BM sections sampled before and during dasatinib treatment, with C/EBPa expression being detectable only after initiation of dasatinib treatment (Figure 1e) .
This case provides proof of prolonged in vivo differentiation of myeloid blasts bearing the t(8;21) to mature, partially functional neutrophilic granulocytes following treatment with a noncytotoxic drug, reminiscent of all-trans retinoic acid in acute promyelocytic leukemia (appearance of clonal granulocytes in the absence of BM hypoplasia, that is, during persistence of the abnormal clone). Interestingly, also low-dose cytarabine, Bexarotene and, very recently, Gefitinib have been shown to induce maturation of myeloid blasts. [9] [10] [11] Dasatinib is also able to inhibit wild-type c-Kit 3 and causes growth arrest in molecularly heterogeneous AML cells. 12 Interestingly, also in vitro dasatinib promotes all-trans retinoic acid-induced differentiation in AML cells through the inhibition of Src family kinases. 13 Finally, residual t(8;21) cells can undergo in vitro differentiation and there are reports of differentiation following chemotherapy. 14, 15 A systematic screen for differential phosphorylation of multiple potential targets, for example, by two-dimensional protein gel electrophoresis in conjunction with an antibody directed against phosphorylation sites, was hampered by lack of further BM samples. It is debatable whether inhibition of c-Kit was the sole mechanism by which dasatinib triggered this remarkable response, as inhibition of another kinase, or even off-target effects, cannot be ruled out when a multi-kinase inhibitor is administered. In conclusion, the striking antileukemic activity of singleagent dasatinib in this case of CBF leukemia provides a rationale for its combination with standard chemotherapy, and recently the German-Austrian AMLSG Cooperative Group has initiated a phase II clinical study in patients with newly diagnosed CBF AML. 16 For patients with relapsed RUNX1/RUNX1T1-positive leukemia and comorbidities or a reduced performance status precluding aggressive therapy, a trial with single-agent dasatinib may be warranted.
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